Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.03. | CAMBIUM BIO LIMITED: Cambium Bio - Release of Shares from Escrow | 1 | ASX | ||
CAMBIUM BIO Aktie jetzt für 0€ handeln | |||||
18.03. | CAMBIUM BIO LIMITED: Notice of change of interests of substantial holder-CMB | - | ASX | ||
18.03. | CAMBIUM BIO LIMITED: FDA Approves Cambium Bio's Potency Assay Strategy for Elate | - | ASX | ||
12.03. | CAMBIUM BIO LIMITED: Change of Directors Interest Notice | 1 | ASX | ||
12.03. | CAMBIUM BIO LIMITED: Notification regarding unquoted securities - CMB | 1 | ASX | ||
12.03. | CAMBIUM BIO LIMITED: Application for quotation of securities - CMB | 1 | ASX | ||
07.03. | CAMBIUM BIO LIMITED: Mr Chiu - Director Appointment and Appedix 3X | 1 | ASX | ||
04.03. | CAMBIUM BIO LIMITED: Results of General Meeting | 1 | ASX | ||
03.03. | CAMBIUM BIO LIMITED: Response to queries re Appendices 3X and 3Z | 2 | ASX | ||
28.02. | CAMBIUM BIO LIMITED: Update - Proposed issue of securities - CMB | - | ASX | ||
27.02. | CAMBIUM BIO LIMITED: Half Year Report and Accounts | - | ASX | ||
25.02. | Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol | 3 | smallcaps.com.au | ||
25.02. | CAMBIUM BIO LIMITED: FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol | 1 | ASX | ||
17.02. | CAMBIUM BIO LIMITED: Final Director Interest Notice-Graham Vesey | - | ASX | ||
17.02. | CAMBIUM BIO LIMITED: Initial and Final Director Interest Notices-Chandra Bala | - | ASX | ||
13.02. | CAMBIUM BIO LIMITED: Placement Shares Cleansing Notice | 4 | ASX | ||
13.02. | CAMBIUM BIO LIMITED: Application for quotation of securities - CMB | 1 | ASX | ||
31.01. | CAMBIUM BIO LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 2 | ASX | ||
30.01. | CAMBIUM BIO LIMITED: Notice of General Meeting/Proxy Form | 2 | ASX | ||
07.01. | CAMBIUM BIO LIMITED: Change in substantial holding | 1 | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 36,200 | -1,92 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
EVOTEC | 5,900 | -0,08 % | RBC stuft Evotec auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Evotec mit einem Kursziel von 11,60 Euro auf "Outperform" belassen. Nach 15 sehr turbulenten Monaten dürfte der nächste wichtige... ► Artikel lesen | |
TEMPUS AI | 46,220 | 0,00 % | Tempus AI, Inc. (NASDAQ:TEM) Sees Significant Increase in Short Interest | ||
BIONTECH | 83,65 | -1,82 % | Lululemon | Ubisoft | Steyr - Curevac mit erstem Erfolg gegen Biontech | Markus Weingran - Mein Tipp: SMARTBROKER+: https://broker-tipp.de/ (Werbung) Willkommen bei der Börsenlounge mit Markus Weingran. Die Themen heute: Lululemon | Ubisoft | Steyr - Curevac mit erstem Erfolg... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,600 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 43,110 | -7,33 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
BEAM THERAPEUTICS | 16,425 | 0,00 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard | ||
AVIDITY BIOSCIENCES | 28,120 | -5,54 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 16,180 | -2,53 % | Arcutis Biotherapeutics, Inc.: Arcutis and Padagis Agree to Stay Patent Lawsuit | WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
OSR HOLDINGS | 2,430 | 0,00 % | OSR Holdings Inc.: OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate ... | SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies... ► Artikel lesen | |
BB BIOTECH | 30,450 | -2,87 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,800 | 0,00 % | Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March | ||
CG ONCOLOGY | 18,750 | -16,41 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
ADMA BIOLOGICS | 19,470 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
ARS PHARMACEUTICALS | 13,415 | +2,80 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen |